EMPEROR-Preserved Benefit Stratification Index

Clinical calculation support · Verify results before clinical use

Patient and baseline risk inputs

Estimate the potential absolute benefit of empagliflozin for the EMPEROR-Preserved primary composite endpoint.

HR 0.79 · Trial follow-up 26.2 mo
Use a non-identifying code where possible.
The model is anchored to the trial's median follow-up of 26.2 months. Changing this label does not time-adjust the risk estimate.
Enter a clinically estimated risk over approximately 2.2 years. If provided, this takes precedence over the feature-based approximation below.
If baseline risk is left blank, the calculator applies pragmatic multipliers to the trial placebo event proportion. These multipliers are not derived from a validated prognostic model.

Clinical context

EMPEROR-Preserved evaluated empagliflozin 10 mg once daily versus placebo in 5,988 patients with heart failure and LVEF greater than 40%, on top of usual therapy. The primary endpoint was cardiovascular death or hospitalization for heart failure.

Trial outcomeEmpagliflozinPlacebo
Primary endpoint13.8%17.1%
Hazard ratio (95% CI)0.79 (0.69–0.90)
Median follow-up26.2 months
Approximate absolute difference in observed event proportions3.3 percentage points

How this calculator works

  • Uses a supplied baseline risk when entered; otherwise starts from the trial placebo event proportion and applies the original feature multipliers.
  • Approximates treated cumulative risk using a proportional-hazards transformation: 1 − (1 − baseline risk)HR.
  • Calculates ARR as baseline risk minus estimated treated risk and NNT as the reciprocal of ARR expressed as a proportion.

References and limitations

Anker SD, Butler J, Filippatos G, et al.
Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021;385:1451–1461.
doi:10.1056/NEJMoa2107038 · PMID: 34449189
Important limitations
The feature multipliers are pragmatic assumptions and have not been validated as a prognostic model. The HR-to-risk transformation is approximate and assumes proportional hazards; it does not reproduce a patient-level survival model or account for competing risks, recurrent hospitalizations, treatment adherence, or subgroup-specific effects.
Clinical use
Use alongside guideline recommendations, contraindications, safety assessment, patient preferences, and clinical judgment. Do not use these estimates as the sole basis for starting or withholding therapy.